Login to Your Account

Innate, BMS Ink $465M Deal for Cancer Antibody IPH2102

By Staff Reports

Thursday, July 7, 2011
Innate Pharma SA's Phase I-stage cancer candidate IPH2102 landed the firm a sizeable up-front payment of $35 million in a potential $465 million collaboration with Bristol-Myers Squibb Co.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription